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Abstract
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a recently identified and potentially useful
plasma biomarker for cardiovascular and atherosclerotic diseases. However, the correlation between the Lp-PLA2
activity and carotid atherosclerosis remains poorly investigated in patients with metabolic syndrome (MetS). The
present study aimed to evaluate the potential role of Lp-PLA2 as a comprehensive marker of metabolic syndrome
in individuals with and without carotid atherosclerosis.
Methods: We documented 118 consecutive patients with MetS and 70 age- and sex-matched healthy subjects
served as controls. The patients were further divided into two groups: 39 with carotid plaques and 79 without
carotid plaques to elucidate the influence of Lp-PLA2 on carotid atherosclerosis. The plasma Lp-PLA2 activity was
measured by using ELISA method and carotid intimal-media thickness (IMT) was performed by ultrasound in all
participants.
Results: Lp-PLA2 activity was significantly increased in MetS subgroups when compared with controls, and was
higher in patients with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant
difference in Lp-PLA2 was obtained between patients with three and four disorders of metabolic syndrome (P < 0.01).
Age (b = 0.183, P = 0.029), LDL-cholesterol (b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410, P = 0.000) emerged as
significant and independent determinants of Lp-PLA2 activity. Multiple stepwise regression analysis revealed that
LDL-cholesterol (b = 0.309, P = 0.000), systolic blood pressure (b = 0.322, P = 0.002) and age (b = 0.235, P = 0.007)
significantly correlated with max IMT, and Lp-PLA2 was not an independent predictor for carotid IMT.
Conclusions: Lp-PLA2 may be a modulating factor for carotid IMT via age and LDL-cholesterol, not independent
predictor in the pathophysiological process of carotid atherosclerosis in patients with MetS.
Background
The metabolic syndrome (MetS) is a constellation of
atherogenic risk factors including abdominal obesity,
hypertension, insulin resistance, dyslipidemia, proinflam-
matory, and prothrombotic state [1]. Recent publications
have probed that patients with MetS are at higher risk of
cardiovascular morbidity and mortality [2] and are more
prone to atherosclerosis than normal subjects, even in
the young adults [3,4]. Although the relationship between
MetS and the risk of cardiovascular disease is still a mat-
ter of debate, MetS has been associated with carotid
plaque formation and intima-media thickening [5].
Inflammatory processes have been increasingly recog-
nized as a critical step in the pathogenesis of both meta-
bolic syndrome and carotid atherosclerosis and may be
important midways linking MetS to the increased arterio-
sclerotic events [6,7].
Lipoprotein-associated phospholipase A2 (Lp-PLA2)
was recently characterized as a novel inflammatory bio-
marker correlated with several components constituting
the MetS and implicated in atherosclerosis, incident car-
diovascular disease [8,9]. Lp-PLA2 is preferentially
secreted by monocytes and macrophages and hydrolyzes
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any medium, provided the original work is properly cited.oxidatively modified low-density lipoprotein by cleaving
oxidized phosphatidylcholines thereby generating lyso-
phosphatidylcholine and oxidized free fatty acids [10].
Such chemoattractants are thought to play pivotal role in
inflammatory reactions and particularly in vascular
inflammation and atherosclerosis [11]. However, the
potential role of Lp-PLA2 in atherogenesis and the anti-
or proatherogenic characteristic of this enzyme in
humans are less well understood [12]. Almost all pro-
spective and nested case cohort studies suggested that
Lp-PLA2 is proatherogenic [13]. One recent trial [14]
demonstrated that symptomatic carotid artery plaques
are characterized by increased levels of Lp-PLA2 and its
product lysoPC in correlation with markers of tissue oxi-
dative stress, inflammation, and instability. In contrast,
previous investigations reported no associations observed
between carotid intima-media thickness and Lp-PLA2
levels in primary hyperlipidemia patients [15,16].
To the best of our knowledge, few studies have explored
the atherosclerotic risk for carotid arteries correlated with
MetS is confounded by an association with activity of
Lp-PLA2. Additionally, carotid intima-media thickness
( I M T )o fa r t e r i e si sau s e f u lmeasure of clinical athero-
sclerosis as assessed noninvasively by ultrasonography.
Alternations in carotid IMT has been validated as a vascular
marker of the progression of atherosclerosis [17]. Therefore,
in the present study, we measured the plasma Lp-PLA2
activity in patients with MetS (including with and without
carotid atherosclerosis) and correlated it with anthropo-
metric parameters and carotid IMT to evaluate the possible
contribution of Lp-PLA2 to carotid atherosclerosis.
Methods
Study Population
A total of 118 patients with MetS (53 men and
65 women, aged from 32 to71 years), were recruited
from the Second Hospital of Shandong University
according to the criteria proposed by the International
Diabetes Federation [18]. Individuals were excluded if
they had a clinical history of cerebrovascular disease or
present neurological abnormalities, cerebral hemorrhage
and severe cardio-renal or nutritional disorders, lipid
and glucose metabolism. The control group consisted of
70 age- and sex-matched healthy subjects who visited
our hospital for a routine physical check-up and without
a history of cardiac disease, hypertension or diabetes
and having normal findings on physical examination,
chest roentgenography, and echocardiography. Informed
consent was obtained from all participants and the
study was approved by the local ethics committee.
Definition of metabolic syndrome
In our study, metabolic syndrome was defined by the pre-
sence of 3 or more of the following conditions based on
the criteria of IDF [18]: (1) visceral obesity: waist circum-
ference was ≥ 90 cm in men and and ≥80 cm in women,
(2) hypertriglycedemia: ≥ 150 mg/dl (1.7 mmol/l) or
specific treatment for this lipid abnormality, (3) low
HDL cholesterol: <40 mg/dl (1.03 mmol/l) in men and
<50 mg/dl (1.29 mmol/l) in women or specific treatment
for this lipid abnormality, (4) hypertension: systolic blood
pressure ≥130 mmHg or diastolic blood pressure
≥85 mmHg or treatment of previously diagnosed hyper-
tension, and (5) impaired fasting glucose concentration
≥100 mg/dl (5.6 mmol/l) or those who had been treated
for type 2 diabetes.
Clinical measurements
The baseline and clinical characteristics of all partici-
pants were determined. The details of age, gender and
the weight and height were obtained, with the body
mass index calculated as the body weight in kilogram
divided by the height in meters squared. Waist circum-
ference was measured at the level of the umbilicus, sys-
tolic and diastolic blood pressures were obtained with a
mercury sphygmomanometer using auscultory methods.
The laboratory measurements were carried out follow-
ing overnight fasting. Blood was collected at baseline for
glucose, HbA1c, total cholesterol, triglycerides, high
density lipoprotein (HDL)-cholesterol and low-density
lipoprotein (LDL)-cholesterol. Serum insulin levels were
determined by a radio-immunoassay kit (Dongya Ltd,
Beijing, China). Insulin resistance was assessed by the
homeostasis model assessment equation [19].
Lp-PLA2 activity assay
The total plasma Lp-PLA2 activity was measured using
a PAF Acetylhydrolase enzyme immunoassay (EIA) kit
(Catalogue No. 760901, Cayman chemical Company,
USA) with a lower limit of sensitivity of 0.02-0.2 umol/
min/ml. Samples were measured in duplicate in a single
experiment. Lp-PLA2 activity was expressed as micro-
moles of platelet-activating factor hydrolyzed per minute
per milliliter of plasma samples and the inter-assay coeffi-
cient of variance was < 5%.
Carotid ultrasonography
All participants were examined in the supine position
(head turned 45°) by the same trained operator with a
high resolution B-mode ultrasonography equipped with
a 5-10 MHz linear array transducer (iE33, Philips Ultra-
sound, Washington, USA). ECG leads were attached to
the ultrasound recorder for on-line continuous heart
rate monitoring. All the images were recorded and
stored on magneto optical disk for later playback and
analysis. The right and left common carotid arteries
(CCAs) and internal carotid arteries (including bifurca-
tions) were evaluated. IMT, plaque extent of the near
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arteries (ICAs) and bifurcations were measured accord-
ing to the ACAPS protocol. AA thickened IMT was
defined as ≥1.0 mm in either carotid artery. Presence of
atherosclerotic plaques, defined as localized lesions with
protrusion into the arterial lumen or regional IMT≥1.1
mm [20], was considered when found in either or both
CCAs. IMT was therefore measured at the point of
maximal thickness in the walls of both CCAs. Maximal
a n dm e a nI M Tw e r ed e f i n e da st h eg r e a t e s ta n dm e a n
values, respectively, of IMT measured from 3 contiguous
sites at 1-cm intervals. Maximal IMT represented the
highest single measurement at any site with plaque.
Both thickened IMT and plaques were reconfirmed by
re-examining the lesions on the printouts from the
ultrasound scanner.
Statistical analysis
Data are presented as mean ± SD for continuous variables
or proportions. After testing for normal distribution of
variables, student’s 2-tail t-test and one-way analysis of
variance (anova) followed by the post hoc least significant
difference test were used where appropriate. The correla-
tions between two variables were assessed by Pearson cor-
relation analysis. Multiple linear regression analysis was
used to evaluate the contribution of independent factors.
Statistical analyses were performed using SPSS v. 15.0
(SPSS, Chicago, IL) software. A two-tailed P value <0.05
was considered statistically significant.
Results
Baseline and clinical characteristics of participants
The baseline and clinical characteristics of the metabolic
syndrome patients and controls were shown in Table 1.
All MetS patients were divided into subgroups according
to presence or absence of plaques, carotid atherosclerotic
plaques was identified in 39 patients, and no stenosis or
occlusion was found. There were no statistical differences
in age or gender among three groups. Patients with MetS
showed increased levels of systolic blood pressure, diasto-
lic blood pressure, BMI, waist circumference, waist-hip
ratio, triglyceride, total cholesterol, fasting glucose, insulin,
HbA1c, HOMA-insulin resistance and more prescription
of medications, and decreased levels of HDL-cholesterol
when compared with controls (all P < 0.05-0.01), but there
were no significant differences in any of those parameters
between patients with and without carotid plaques. LDL
cholesterol was found to increase from controls to MetS
patients with and without carotid plaques, moreover, with
significant difference between two patient subgroups (P <
0.05). Mean IMT values were significantly higher in MetS
patients with and without carotid plaques than in controls
(0.74 ± 0.11 mm vs. 0.51 ± 0.15 mm, 0.86 ± 0.20 mm vs.
0.51 ± 0.15 mm, all P < 0.01, respectively), and were
highest in patients with carotid plaques. Max IMT values
increased significantly in MetS patients with carotid pla-
ques, whereas no difference was found between the other
two groups.
Lp-PLA2 activity
Distribution of Lp-PLA2 activity approximates a nor-
mal distribution. Lp-PLA2 activity was significantly
increased in MetS subgroups when compared with
controls (all P < 0.01), and was higher in patients with
carotid plaques than those without plaques (34.10 ±
9.51 umol/min/mL vs. 29.62 ± 8.98 umol/min/mL, P <
0 . 0 5 )( T a b l e1 ,F i g u r e1 ) .T h e r ew e r en oa g e( < 6 5v s .
≥65 years) and gender differences of Lp-PLA2 activity
in patients (Data not shown). To assess the association
of metabolic syndrome components with Lp-PLA2
activity, we further found that significant difference in
Lp-PLA2 was obtained between patients with three
(n = 89) and four (n = 28) disorders of metabolic
syndrome (38.79 ± 9.22 umol/min/mL vs. 30.60 ±
9.58 umol/min/mL, P <0 . 0 1 ) .
Relationship of Lp-PLA2 activity and determinant factors
In simple regression analyses, Lp-PLA2 activity corre-
lated positively with age (r = 0.250, P = 0.006), total
cholesterol (r = 0.371, P = 0.000), LDL-cholesterol (r =
0.402, P = 0.000), glucose (r = 0.188, P = 0.042) and
HbA1c (r = 0.188, P = 0.042) in the patients with MetS.
We also found Lp-PLA2 activity correlated with waist-
hip ratio weakly but not significantly (r = 0.174, P =
0.061). However, in multivariable stepwise regression
analyses, age (b = 0.183, P = 0.029), LDL-cholesterol
(b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410,
P = 0.000) emerged as significant and independent
determinants of Lp-PLA2 activity (Table 2).
Relationship of max IMT and risk factors
Pearson’s correlation coefficient and multiple regres-
sion analysis were performed to examine the relation-
ship of max IMT to Lp-PLA2 activity and other
biomarkers in overall MetS patients in order to identify
a parameter that reflects carotid atherosclerosis.
As shown in Table 3, Lp-PLA2 activity (r = 0.199,
P = 0.023), LDL-cholesterol (r = 0.333, P = 0.000), age
(r = 0.325, P = 0.000) and systolic blood pressure (r =
0.225, P = 0.015) were significantly correlated with
max carotid IMT. Unexpectedly, in multiple stepwise
regression analysis, Lp-PLA2 activity correlated with
the presence of atherosclerosis weakly but not signifi-
cantly (b =0 . 1 4 6 ,P = 0.097). Our results revealed that
only LDL-cholesterol (b = 0.309, P = 0.000), systolic
blood pressure (b =0 . 3 2 2 ,P = 0.002) and age (b =
0.235, P = 0.007) were the significant predictors of
max IMT. Moreover, after adjustment for age and lipid
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and carotid IMT did not reach statistical significance.
Discussion
The present study identified elevated total plasma
Lp-PLA2 activity in patients with the MetS, especially in
those with carotid atherosclerosis when compared to the
control subjects. We demonstrated that the Lp-PLA2
activity correlated with age, LDL-cholesterol and waist-
hip ratio in patients with metabolic syndrome. Unfortu-
nately, our data provided no evidence that Lp-PLA2
Table 1 Baseline and clinical characteristics of the MetS subgroups and controls
Variables Controls MetS
No carotid plaque With carotid plaque
Number 70 79 39
Sex (male/female) 30/40 35/44 18/21
Age (years) 52.4 ± 8.8 53.8 ± 7.8 55.4 ± 6.6
BMI (kg/m
2) 24.49 ± 2.22 28.99 ± 4.05 28.07 ± 3.45
Waist circumference (cm) 84.51 ± 8.05 98.08 ± 10.16 96.45 ± 8.58
Waist-to-hip ratio 0.86 ± 0.05 0.92 ± 0.06 0.93 ± 0.08
Systolic BP (mmHg) 116 ± 10 151 ± 22 152 ± 23
Diastolic BP (mmHg) 77 ± 7 95 ± 14 94 ± 13
Total cholesterol (mmol/L) 4.42 ± 0.78 5.36 ± 1.12 5.55 ± 0.99
Triglyceride (mmol/L) 0.99 ± 0.42 2.34 ± 1.19 2.23 ± 0.94
HDL cholesterol (mmol/L) 1.53 ± 0.33 1.22 ± 0.31 1.25 ± 0.26
LDL cholesterol (mmol/L) 2.82 ± 0.72 3.63 ± 0.88** 4.03 ± 0.99**▲
Glucose (mmol/L) 4.99 ± 0.54 6.37 ± 2.09** 6.76 ± 3.01**
Insulin (uU/mL) 12.15 ± 5.37 21.39 ± 12.09** 19.63 ± 10.20**
HbA1c( % ) 4.58 ± 0.32 5.38 ± 1.05 5.57 ± 1.52
HOMA-insulin resistance 2.74 ± 1.38 6.24 ± 4.90** 5.83 ± 3.45**
Mean IMT (mm) 0.51 ± 0.15 0.74 ± 0.11 0.86 ± 0.20▲▲
Max IMT (mm) 0.61 ± 0.52 0.77 ± 0.09 1.87 ± 0.73▲▲
Lp-PLA2 activity 24.14 ± 6.33 29.62 ± 8.98** 34.10 ± 9.51**▲▲
Medifications
Aspirin - 70(88%) 35(91%)
Anti-hypertensive drugs - 30(38%) 17(43%)
Oral hypoglycaemic drugs - 9(12%) 4(11%)
Lipid regulating agents - 9(12%) 5(14%)
Values are mean ± SD; *P < 0.05 and **P < 0.01 compared to control; ▲P < 0.05 and ▲▲P < 0.01 compared to MetS without carotid plaque.
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Figure 1 Lp-PLA2 activity in the MetS subgroups and controls.
Table 2 Linear regression analysis of variables correlated
with Lp-PLA2 in Mets patients
Simple Multiple
rPb P
Age (years) 0.250 0.006 0.183 0.029
Sex 0.164 0.076 0.185 0.073
BMI (kg/m2) -0.092 0.326 0.148 0.270
Waist-to-hip ratio 0.174 0.061 0.410 0.000*
Systolic BP (mmHg) -0.081 0.386 -0.068 0.407
Diastolic BP (mmHg) -0.150 0.106 -0.065 0.435
Total cholesterol (mmol/L) 0.371 0.000 0.065 0.618
Triglyceride (mmol/L) 0.082 0.380 0.065 0.791
HDL cholesterol (mmol/L) -0.025 0.786 -0.071 0.407
LDL cholesterol (mmol/L) 0.402 0.000 0.401 0.000*
Glucose (mmol/L) 0.188 0.042 0.084 0.305
Insulin (uU/mL) -0.153 0.099 -0.122 0.142
HbA1c 0.188 0.042 0.084 0.305
HOMA-insulin resistance -0.069 0.458 -0.084 0.311
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patients. The associations of Lp-PLA2 activity with caro-
tid atherosclerosis may be mediated through age and
LDL-cholesterol level.
The biological mechanisms involving plasma Lp-PLA2
in the pathogenesis of the MetS and atherosclerosis are
not well-characterized. Recent evidence suggests inflam-
mation is an important pathogenic factor in atherosclero-
sis and coronary heart disease, particularly in the context
of insulin resistance, obesity [21], and the metabolic syn-
drome [6]. Furthermore, atherosclerosis is now recog-
nized as manifestations of vascular inflammation [7].
Inflammatory factors such as adhesion molecules
(ICAM-1 and VCAM-1), CD40 ligands, C-reactive pro-
tein (CRP) and myeloperoxidase (MPO) participate in
induction of insulin resistance and atherosclerotic disease
[21,22]. Lp-PLA2, originally named platelet-activating fac-
tor acetylhydrolase (PAF-AH), is an enzyme involved in
lipoprotein metabolism and inflammatory pathways [10].
In human, 80% of Lp-PLA2 circulates bound to LDL-
cholesterol, 10-15% circulates with HDL-cholesterol, and
the remaining 5-10% circulates with VLDL-cholesterol
[18]. Lp-PLA2 enzymatic activity results in generation of
lysophosphotidylcholine (lysoPC) and oxidized non-
esterified fatty acids, two pro-inflammatory mediators
[10]. The lysoPC stimulates macrophage proliferation,
up-regulates cytokines and CD40 ligands, and increases
the expression of vascular adhesion molecules, implying
a complex interaction between Lp-PLA2 and other
inflammatory mediators [23,24]. Based on that, Lp-PLA2
has been implicated in inflammation and considered as
an inflammatory marker in the MetS. Recently, several
epidemiological studies demonstrate that an elevated
activity of Lp-PLA2 is associated with MetS and number
of the metabolic syndrome components as well as inci-
dent fatal and non-fatal CVD regarding MetS [25,26]. In
the current study, we observed that plasma Lp-PLA2
activity was higher in patients with the MetS than in con-
trols, suggesting that Lp-PLA2 activity may increase sig-
nificantly when metabolic syndrome was present.
Furthermore, our findings showed that there was a linear
rise in Lp-PLA2 activity with an increment of number of
metabolic syndrome components. These data were in
line with previous research [19] and enlarged our scope
for potential role of Lp-PLA2 in patients with MetS.
Results for studies of the associations of components of
MetS with Lp-PLA2 activity have shown that abdominal
obesity may have been independently responsible for the
changes of Lp-PLA2 observed in this study. Additionally,
we found Lp-PLA2 correlated with glucose and HbA1c
weakly but significantly only in simple regression. Our
findings were in accordance with the previous studies, in
which Lp-PLA2 correlated with abdominal adiposity
[27,28] but differed from the results of Noto et al [25]
and Rana et al [29], who found that plasma Lp-PLA2
activity did not appear to be associated with waist cir-
cumference. It was possible that obesity was associated
with decreases in local and peripheral insulin resistance
[30]. Adipose tissue located in intra- abdominal or visc-
eral cavities is likely to be infiltrated by macrophage,
which is an important cause of the inflammatory state
associated with abdominal obesity and the metabolic
syndrome [29]. Lp-PLA2, as an inflammatory marker, is
mainly secreted by macrophages. Thus, our results sug-
gested that central obesity may contribute to the
Lp-PLA2 activity changes in patients with MetS. Out
results also indicated that there was parallel increase in
Lp-PLA2 activity with an increment of components of
metabolic syndrome, which was consistent with the find-
ings of Noto at al. [25].
In the present study, our results have shown that
Lp-PLA2 activity was elevated among MetS patients
with carotid plaques. However, we further found inde-
pendent determinants for thickened IMT as being
LDL-cholesterol and age in multiple regression models.
The Lp-PLA2 activity was not independently facilitates
the morbidity of carotid atherosclerosis. Previous studies
h a v er e v e a l e dt h ep l a s m aL p - P L A 2 activity in athero-
sclerotic disease, but consensus is still lacking [8,9,31].
Biologically, Lp-PLA2 is a vascular-specific proinflamma-
tory enzyme that operates physiologically in the arterial
intima [32]. Evidence has shown that Lp-PLA2 is
expressed in human and rabbit atherosclerotic plaques
[33]. Vickers et al [34] revealed that carotid tissue con-
centrations of Lp-PLA2 was notably very high in the
rupture-prone shoulder region of thin fibrous cap ather-
omas, and Lp-PLA2 colocalized with macrophages and
oxidized LDL in atherosclerotic carotid plaques.
Table 3 Linear regression analysis of risk factors
correlated with max-IMT in Mets patients
Simple Multiple
rPb P
Age (years) 0.325 0.000 0.235 0.007
Sex 0.011 0.907 0.226 0.112
BMI (kg/m2) 0.128 0.245 0.092 0.274
Waist-to-hip ratio 0.071 0.449 0.016 0.874
Systolic BP (mmHg) 0.225 0.015 0.322 0.002
Diastolic BP (mmHg) 0.108 0.245 0.097 0.285
Total cholesterol (mmol/L) 0.119 0.200 0.065 0.541
Triglyceride (mmol/L) 0.052 0.573 0.013 0.882
HDL cholesterol (mmol/L) -0.039 0.676 -0.008 0.927
LDL cholesterol (mmol/L) 0.333 0.000 0.309 0.000
Glucose (mmol/L) 0.113 0.225 0.104 0.201
HbA1c 0.113 0.225 0.104 0.201
HOMA-insulin resistance 0.007 0.940 0.011 0.893
Lp-PLA2 0.199 0.023 0.146 0.097
Gong et al. Lipids in Health and Disease 2011, 10:13
http://www.lipidworld.com/content/10/1/13
Page 5 of 8However, several clinical studies suggested that prema-
ture coronary atherosclerosis [31] as well as carotid
intima-media thickness plasma was not influenced by
Lp-PLA2 activity and gene polymorphisms in hypercho-
lesterolemic individuals [15,16]. Thus, consistent with
r e s u l t so fp r e v i o u ss t u d y[ 3 5 ] ,r o l eo ft h i se n z y m ei n
predicting independently the thicken IMT attenuated in
our study, especially after adjustment for age and lipid
variables.
Although the exact mechanisms underlying contribution
of Lp-PLA2 to carotid atherosclerosis in MetS patients
remain to be elucidated, there are several possible explana-
tions. Firstly, our study demonstrated that lipid parameters
may contribute to Lp-PLA2 activity changes. An increase
in plasma Lp-PLA2 activity, reflecting LDL-cholesterol
values, has been established in several investigations [9,36].
Stafforini et al investigated that Lp-PLA2 participated in
the key oxidative steps of atherogenesis due to the associa-
tion of Lp-PLA2 and LDL-cholesterol via an interaction
with apolipoprotein B (apoB) [37]. Kawamoto et al [38]
reported that LDL-cholesterol was independently asso-
ciated with carotid atherosclerosis in addition to clustering
of cardiovascular risk factors regarding MetS. Several stu-
dies [39-41] suggested that the components of metabolic
and LDL-cholesterol played a role to synergistically influ-
ence vascular thickness. Our results revealed that levels of
LDL-cholesterol were significantly increased in MetS
patients with carotid plaques than those without. Sec-
ondly, in present study, multivariate linear regression
showed that age had a similar positive association with
Lp-PLA2 activity and contributed strongly to the variation
in IMT. Thus, taken together previous important results
[38-41] and our intriguing findings implied that Lp-PLA2
activity was intimately associated with carotid thicken
IMT and atherosclerosis via correlation with age and
LDL-cholesterol in our study. Lp-PLA2 may be a modulat-
ing factor in the process of carotid atherosclerosis. Lastly,
owing to the prominent biological activities, the opposing
proinflammatory and antiatherogenic properties of
Lp-PLA2 have been demonstrated both in human and ani-
mal models. In rabbit models, administration of Lp-PLA2
inhibited myocardial ischemia/reperfusion injury [42], and
local expression of Lp-PLA2 reduced accumulation of oxi-
dized LDL-cholesterol in balloon-injured arteries [43].
However, previous findings did not ascertain a causal rela-
tionship between Lp-PLA2 and the clinical consequences
of atherosclerotic disease in patients with primary hyperli-
pidemia [15,16] and diabetes mellitus [44]. Interestingly,
elevated Lp-PLA2 has been identified in human sympto-
matic carotid atherosclerotic plaque and its product lyso-
phosphatidylcholine (lysoPC) correlated with markers of
tissue oxidative stress, inflammation, and instability [14].
These paradoxical results may partly be explained by the
relatively small study populations and selected inclusion
criteria. Further studies are required to clarify whether
Lp-PLA2 is a risk marker that participates in the pathogen-
esis of carotid atherosclerosis in patients with MetS.
Despite of interesting findings, potential limitations of
this study merit consideration. Our results are based on
single measurements of circulating Lp-PLA2, which may
not reflect the true activity of Lp-PLA2 over time or
true expression in carotid atherosclerotic plaques. For
this reason, further outcome-directed prospective studies
would give insight into the significance of Lp-PLA2
activity versus expression in atherosclerotic plaques.
Several studies have shown that activity of Lp-PLA2 was
impacted by lipid-lowering drugs such as statins and
fibric acid derivatives (fibrates)[25,45]. Thus, we could
not eliminate the possible effect of medications for
Lp-PLA2 activity on the present findings. Finally, even
though intriguing, results obtained in further confirma-
tory studies need to be considered to clarify the validity
of Lp-PLA2 in large series of patients.
Conclusions
In conclusion, our results of increased plasma Lp-PLA2
activity in patients with the metabolic syndrome, espe-
cially in those with carotid atherosclerosis, suggest that
Lp-PLA2 may be an inflammatory marker of metabolic
syndrome. However, multiple stepwise regression analy-
sis suggested that Lp-PLA2 may be a modulating factor,
not independent risk predictor in the pathophysiological
process of carotid atherosclerosis in MetS patients.
Because Lp-PLA2 activity may represent a novel pathway
associated with thicken IMT, further research using
large samples and general population need to be done
to clarify the exact role of Lp-PLA2 on carotid athero-
sclerosis in metabolic syndrome subjects.
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